On June 3, the U.S. FDA released a highly anticipated draft guidance, focused on how to bring cutting-edge CGT products, such as gene editing therapies, to patients more efficiently.

 

The draft proposal suggests that sponsors can leverage publicly available information and mature "platform knowledge" – covering chemistry, manufacturing, and control (CMC) data, non-clinical studies, and clinical experience – to streamline the regulatory submission process and avoid redundant verification. Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research (CBER), explicitly stated that this move aims to "accelerate innovation without compromising rigorous scientific standards," enabling patients with rare, life-threatening diseases and few treatment options to access therapies more quickly.

 

The industry views this document as a significant "loosening" signal from the FDA in the CGT field. Complementing this is a draft guidance recommending the use of next-generation sequencing technologies to assess off-target editing risks, and an initiative encouraging companies to engage with regulators through INTERACT meetings as early as possible in product development (even before an IND submission).

 

Vijay Kumar, Acting Director of the Office of Therapeutic Products, further explained that leveraging existing knowledge does not mean lowering standards; rather, it aims to improve overall efficiency while maintaining the highest safety and efficacy standards.

 

However, shifting focus from Washington's regulatory buildings to the global drug innovation arena reveals a more complex picture. The FDA's efficiency-enhancing move is not only an evolution of scientific regulation but also a proactive response from the U.S. in a competition involving industrial competitiveness and clinical validation speed.

 

And its most powerful reference point is rapidly rising on the other side of the Pacific.

 

TONACEA 01: China in the Fast Lane

 

The time lag the FDA is trying to reduce through "platform knowledge reuse" has already been dramatically compressed in China through other means.

 

According to a recent McKinsey report, China has shortened the timeline from early drug discovery to IND application by 50% to 70%. By 2023, China's share of global clinical research had risen to 39%, surpassing the U.S. and EU in patient enrollment and development speed.

 

This efficiency advantage is not solely cost-driven. A deeper reason lies in a unique institutional arrangement for clinical research: investigator-initiated trials (IITs).

 

Unlike the traditional IND pathway requiring regulatory review, in China, IITs initiated by researchers at medical institutions can begin human studies after only ethics committee approval and filing (statutory timeline of 5 working days). For cutting-edge fields like CGT, the administrative waiting period for entering human trials is compressed to a window measured in working days, a stark contrast to the months-long cycles of traditional IND review.

 

Over the past decade, the number of IITs in China has exploded. By 2024, relevant studies had systematically analyzed over 1,000 IITs.

 

On May 1, 2026, the "Regulations on the Clinical Research and Clinical Translational Application of New Biomedical Technologies" (Decree No. 818) officially came into effect. For the first time, this regulation establishes a framework for cutting-edge technologies like gene editing and cell therapy, aiming to further shorten the path to clinical entry while ensuring standardization.

 

John Wu, Managing Director of Boston Consulting Group's (BCG) healthcare practice, commented that this approach allows certain innovative products to "rapidly enter human trials," bypassing the initial hurdles of lengthy U.S.-style approvals.

 

This chain of "early clinical signal, then formal development" restructures what was a linear, long-cycle process into a highly parallel, closed loop, dramatically compressing the timeline from target discovery to value validation.

 

It is this visible speed that has attracted multinational pharmaceutical companies in droves. In just the first three months of 2026, the total value of out-licensing deals by Chinese companies exceeded US$60 billion, putting the year on track to surpass the US$130 billion record set in 2025.

 

AstraZeneca recently announced a US$15 billion investment to strengthen R&D operations in China. Robert Plenge, Chief Research Officer at BMS, publicly acknowledged: "One very interesting aspect of China is that we can test more programs in early development, allowing us to obtain clinical proof-of-concept more efficiently."

 

Large pharma needs have undergone a structural shift. Evaluate data shows that platform deals are replacing single-asset licenses as the mainstream model for U.S.-China collaborations. U.S. companies are now licensing entire AI drug discovery engines, antibody discovery systems, or siRNA portfolios in a single agreement, gaining multiple "shots on goal."

 

Correspondingly, Chinese biotechs, armed with early clinical data, are commanding higher upfront payments (average of US$167 million in 2026, a 36% year-on-year increase), while accepting single-digit royalties. The essence of this deal logic is that China's low-cost clinical validation capability pushes molecules past the value inflection point, for which global pharma pays a premium.

 

TONACEA 02: When Science Encounters a Security Review List

 

However, just as efficiency logic is driving deep U.S.-China biomedical integration, a political force is pulling in the opposite direction.

 

In May 2026, Republican Rep. John Moolenaar of Michigan and Democratic Rep. Debbie Dingell jointly introduced the "Biotechnology Investment National Security Act of 2026," which would add biotechnology to the Treasury Department's outbound investment review list, targeting cross-border license agreements, joint ventures, and equity investments between the U.S. and China.

 

Moolenaar has publicly labeled deals between Pfizer, BMS, and Chinese companies as "dangerous transactions," and has even pushed for language in Congress to prohibit the inclusion of clinical data generated in China in IND submissions to the FDA.

 

If this protectionist wave materializes, it would fundamentally cut off the pathway for Chinese IIT data to provide early evidence for U.S. registrational trials, leading to a decoupling of the two countries' clinical validation systems.

 

Paradoxically, the FDA's own requirement – that any drug approval must have at least 20% of the trial conducted within the U.S. – had already created an "American anchor": China could serve as an efficient proof-of-concept accelerator, but final registrational evidence must be grounded in the U.S.

 

This arrangement previously achieved a delicate balance between efficiency and regulatory sovereignty. The new legislative proposals, by attempting to further cut off the flow of early data, could corner the R&D logic of multinational companies.

 

Pharma's stance is therefore complex and divided.

 

On one hand, there is scientific pragmatism – as long as "equally rigorous controls" are used, data, regardless of where the study is conducted, can guide global clinical trial design.

 

On the other hand, there is geopolitical risk aversion. James Foster, CEO of large CRO Charles River Labs, acknowledged that while companies face political pressure to reconsider investments in China, they are equally aware that "a drug approved in China must be tested in China."

 

In anxiety, pharmaceutical giants are adopting a "dual-track" strategy: deeply embedding early R&D and clinical validation in China to gain speed advantages, while ensuring that confirmatory studies in the U.S. and Europe are sufficient to meet regulatory requirements.

 

TONACEA 03: Let Patients Define the Endgame

 

This situation leads global biopharma to a critical question: who should govern the speed and cost of clinical validation, and by what rules?

 

The FDA's regulatory "loosening" in the field of gene editing therapies is essentially trading time for scientific progress – an internal process optimization without lowering safety standards. But the pressure of external competition will not abate as a result.

 

The speed flexibility that China's institutional framework provides for clinical research has profoundly reshaped the global drug innovation chain. As Eric Green, CEO of Trace Neuroscience, noted, China's rise demonstrates the power of clinical data, even when drawn from smaller patient populations.

 

Meanwhile, the forcible intervention of geopolitics risks turning this competition from a benign race into a zero-sum one. The ultimate cost of restricting the drugs and data the U.S. can access will be borne by patients waiting for new treatments.

 

Europe is already feeling similar growing pains. The EU's share of global clinical trials fell from 22% in 2013 to 12% in 2023. The European Commission is now pushing back through the Biotechnology Act, attempting to compress multinational trial authorization times from 75 days to 47 days.

 

Major global pharmaceutical innovators are all using different institutional tools to compete for the strategic high ground of "clinical validation." But regardless of how policies evolve, the lives that cannot wait must never be betrayed.

 

Mo Trikha, CEO of Kivu Bioscience, said in a recent industry discussion that faced with competition from China, "we have to embrace it and build a Golden Gate Bridge." The two ends of this bridge should connect not political directives for decoupling, but an efficiency race based on scientific consensus and patient interests.

 

References:

1. FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients; FDA

2. Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals.; Biospace

3. No longer a bargain pool, Chinese biotechs command higher premiums; Biospace

4. Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech; Endpoints